Skip to main content
Header logo
BioInvent Logo
Main Top Navigation
  • Career
  • Contacts
  • About us Open link menu
    About us
    • Working at BioInvent
    • Management
    • Board of Directors
    • Our Operations
    • Sustainability
    • Our Purpose & Strategy
    • Our Stories
    • Our History
    Portfolio strategy

    BioInvent has a long history and a strong position in the generation and development of antibody drugs. The foundation of the company is expertise in immunology, cancer biology and antibody biology. Today, BioInvent is a company with multiple clinical programs ongoing. 

    about us nav image

    The unique development tool F.I.R.S.T™, where patient material is the foundation throughout the development process, simultaneously identifies the clinically most relevant targets in a disease model and matching antibodies. The proprietary antibody library n-CoDeR® contains antibodies that bind specifically and strongly to their targets.

  • Clinical programs Open link menu
    Clinical programs
    • Pipeline
    • Our Programs Open link menu
      Our Programs
      • BI-1808 in T-cell Lymphoma
      • BI-1808 in solid tumors
      • BI-1206 in NHL
      • BI-1206 in solid tumors
      • BT-001 in solid tumors
    • Patients & Medical Professionals
    Exciting and unique pipeline

    BioInvent is a clinical-stage company that discovers and develops antibodies for cancer therapy. The company has one of the most exciting and unique cancer immunotherapy pipelines of any European biotech company.

    View our Clinical Pipeline.

    Exciting and unique pipeline image

    A solid scientific understanding, a clear clinical development strategy, and a robust capacity to execute plans have put the company on a very promising track to develop treatments capable of transforming the life of cancer patients.

  • Our Science Open link menu
    Our Science
    • Discovery & Innovation
    • Preclinical Programs
    • Manufacturing
    • Technology
    • Scientific publications
    Cutting-edge Science

    BioInvent’s screening platform F.I.R.S.T™, where patient material is the foundation throughout the discovery and development process, identifies both clinically relevant targets and matching antibodies. The proprietary antibody library n-CoDeR® contains antibodies that bind specifically and strongly to their targets.

    Manufacturing
    GMP facilities in-house

    BioInvent Manufacturing, the contract manufacturing business unit of BioInvent International AB, has a proven track record for clients and partners since 1988. Using single use technology for more than 25 years, BioInvent Manufacturing has produced drug substance for clinical trials in Europe, the USA, Japan and Australia.

  • Partners
  • Investors Open link menu
    Investors
    • Investment Case
    • Financial reports
    • Annual reports
    • Events Calendar
    • Share Price
    • Insider trading
    • Sustainability
    • Analysts
    • Ownership
    • Prospect Open link menu
      Prospect
      • New share issue 2021
      • New share issues 2020
      • Archive
    • Corporate Governance Open link menu
      Corporate Governance
      • Code of Conduct
      • Article of Association
      • General Meetings
      • Nominating Committee
      • Board of Directors and Auditors
      • Committees
      • Guidelines for Remuneration
      • Incentive Programs
      • Corporate Governance Reports
    • Video & interview archive
    • Investor Contact
    • Subscribe
    • Financial statistics
    Attractive space
    BioInvent targets a commercially very attractive space in the pharmaceutical landscape – with potential to expand into new territories. BioInvent has a strong deal-making track record, and has ongoing collaborations with companies such as CASI, Merck, Daiichi and Mitsubishi Tanabe.
    Broad clinical pipeline image
    Broad clinical pipeline

    BioInvent is broadening and developing an exciting pipeline of innovative immuno-oncology therapies, based on its unique F.I.R.S.T™ technology platform and n-CoDeR® antibody library.

  • News & Events Open link menu
    News & Events
    • Press Releases
    • Events Calendar
    • Multimedia Library
    • Media Contacts
    BioInvent news and events

    In this section you find all press releases, planned and past events as well as an image bank.

    We are happy to answer any questions, don't hesitate to reach out to us!

  • EN Current language English, click to switch language
  • SV Switch to Swedish
    • EN Current language English, click to switch language
    • SV Switch to Swedish
  • Please fill out this field
Please fill out this field

Breadcrumbs

  • Home
  • News & Events
  • Press Releases

Press Releases

Jun 01, 2011
BioInvent successfully completes private placement of approximately SEK 136 million
Jun 01, 2011
BioInvent successfully completes private placement of approximately SEK 136 million
May 31, 2011
BioInvent announces launch of private placement of new shares
May 31, 2011
BioInvent announces launch of private placement of new shares
May 16, 2011
BioInvent and ThromboGenics Announce the Start of New Study of Novel Antibody Anti-Cancer Agent TB-403 (Anti-PlGF) by Partner Roche
Apr 27, 2011
BioInvent and ThromboGenics Have Dosed the First Patient in Phase IIb Trial of TB-402 (Anti-Factor VIII) for Venous Thromboembolism(VTE)Prophylaxis

Pagination

  • First page
  • Previous page
  • …
  • Page 76
  • Current page 77
  • Page 78
  • Page 79
  • …
  • Next page
  • Last page
X

 

Annual report 2025

Download Annual report here

Share price
Quick links
  • Home
  • About Us
  • Our Business
  • Investors
  • Subscribe
  • Contact Us
Keep up to date on social media
Footer
  • Disclaimer
  • Privacy
  • Site Map
  • Cookie settings
  • Copyright © 2025